NodThera
NodThera is a biotech focused on the discovery and development of NLRP3 inflammasome inhibitors for the treatment of diseases driven by chronic inflammation.
The privately-held UK-based firm was formed in August 2016 when it spun out of the Polish biotech firm Selvita, which remains an investor along with the likes of Sofinnova Partners, 5AM Ventures, Epidarex Capital and F-Prime Capital Partners.
In June 2018, NodThera secured £28 million ($40 million) in a series A financing.
Latest NodThera News & Features
12 October 2020
3 June 2020
20 September 2019
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze